Know Cancer

forgot password

Pilot Study of Adjuvant Fractionated Stereotactic Radiotherapy Following Surgical Removal of Cerebral Metastases

18 Years
Not Enrolling
Metastatic Cancer

Thank you

Trial Information

Pilot Study of Adjuvant Fractionated Stereotactic Radiotherapy Following Surgical Removal of Cerebral Metastases

OBJECTIVES: I. Assess the safety and tolerability of focal stereotactic radiotherapy to the
surgical bed following excision of cerebral metastases, as an alternative to whole brain
irradiation. II. Measure the local relapse rate at the surgical site after surgery and
stereotactic radiotherapy in patients with cerebral metastases. III. Measure the regional
relapse rate, in the brain but away from the treated site, following treatment in these

OUTLINE: All patients undergo surgical removal of their cerebral metastases followed by
adjuvant fractionated stereotactic radiotherapy daily for 5 days. Patients are given up to 5
weeks following surgery to recover and reach the required performance status. Radiotherapy
must commence within 6 weeks of surgery. Patients are followed at 2 weeks after treatment,
monthly for 6 months, every 3 months for the next 18 months, every 6 months for the next
year, and then annually for years 3-5.

PROJECTED ACCRUAL: There will be 20-40 patients accrued into this study.

Inclusion Criteria:

- Histologically confirmed cerebral metastases post surgical resection

- No greater than 3 cerebral metastases postresection

- Gross resection at operation as documented in operation note and postoperative MRI
Patients must have current surgical sites that have not been previously irradiated

- No other indication for whole brain irradiation (i.e., multiple untreated metastases
not suitable for single fraction stereotactic radiotherapy, leptomeningeal disease)

- Age: 18 and over

- Karnofsky 60-100%

- Life expectancy: At least 3 months

- Prior or concurrent required steroids allowed

- Prior stereotactic radiotherapy of cerebral metastases allowed provided no prior
irradiation of current surgical sites

- Prior surgery of cerebral metastases allowed

Exclusion Criteria:

- severe asthma requiring therapy

- allergy to iodine or contrast media

- pregnant

- concurrent chemotherapy

- prior whole brain irradiation or focal irradiation to current sites of disease

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

Judith M. Ford, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Jonsson Comprehensive Cancer Center


United States: Federal Government

Study ID:




Start Date:

March 1997

Completion Date:

Related Keywords:

  • Metastatic Cancer
  • tumors metastatic to brain
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplasms, Second Primary



Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781